A year after bursting onto the scene amid the RNA renaissance, scientific challenges and regulatory resistance have held back ...

Chimeron has developed a novel nanoparticle technology platform called ChaESAR (chimera-encased self-amplifying RNA) that harnesses the properties of self-amplifying RNA (saRNA) and synthetic ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

structured RNAs and amplify short RNA templates. The research “has extended the capabilities of RNA to RNA polymerization in ways that have not been achieved before,” said Scott Silverman of the ...

Synthetic RNA platforms allow for rapid ... to individual treatments or rapidly emerging disease outbreaks. Self-amplifying RNAs have shown enhanced antigen expression at lower doses compared ...

Keylicon Biosciences is a biotechnology company dedicated to developing innovative RNA-based therapeutics. With a focus on self-amplifying RNA technology, Keylicon strives to create safer ...